| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Rebaudioside I (Reb I) interacts with multiple molecular targets. It binds to and activates specific bitter taste receptors, including Tas2r108, Tas2r123, and Tas2r134 in mice . Through activation of these receptors, Reb I stimulates the release of glucagon-like peptide-1 (GLP-1) from enteroendocrine cells via bitter taste signaling pathways in a concentration-dependent manner . Additionally, Reb I interacts with glucosyltransferase enzymes, which facilitate its bioconversion from rebaudioside A by adding a sugar unit with a 1→3 linkage . No specific IC₅₀, Ki, or EC₅₀ values are reported in the available literature.
|
|---|---|
| ln Vitro |
Rebaudioside I (Reb I) has demonstrated the ability to stimulate GLP-1 release from enteroendocrine cells via bitter taste signaling pathways in a concentration-dependent manner . In biochemical studies, Reb I interacts with glucosyltransferase enzymes that facilitate the bioconversion of rebaudioside A to Reb I by adding a sugar unit with a 1→3 linkage . Research on steviol glycosides, including Reb I, has shown that these compounds can activate the PI3K/Akt signaling pathway, which is crucial for glucose transport in cells . Reb I has also been investigated for its potential effects on metabolic pathways and its role as a non-caloric sweetener . The compound exhibits stability under controlled laboratory conditions and does not show significant degradation under appropriate storage . In solubility studies, Reb I shows limited solubility in ethanol (0.5 mg/mL, 0.44 mM) with ultrasonic and heating assistance .
|
| ln Vivo |
Rebaudioside I (Reb I) exhibits dose-dependent effects in animal models. At lower dosages, Reb I has been shown to stimulate GLP-1 release and improve glucose homeostasis . The compound has been investigated for its potential antihypertensive effects, as steviol glycosides can inhibit calcium influx into vascular smooth muscle cells, leading to relaxation and reduced vascular resistance . Reb I also demonstrates potential antidiabetic properties by influencing glucose metabolism and enhancing glucose uptake in various cell types, mimicking insulin effects . Toxicity studies indicate that Reb I is generally safe, though high doses should be approached with caution . The compound also exhibits antioxidant effects that help mitigate oxidative stress in cells .
|
| Enzyme Assay |
Studies have demonstrated that Reb I interacts with glucosyltransferase enzymes, which facilitate the bioconversion of rebaudioside A to Reb I by adding a sugar unit with a 1→3 linkage . Additionally, Reb I binds to bitter taste receptors including Tas2r108, Tas2r123, and Tas2r134 in mice, triggering signal transduction pathways that lead to GLP-1 release .
|
| Cell Assay |
Research has shown that Reb I affects various cellular processes, including the stimulation of GLP-1 release from enteroendocrine cells via bitter taste signaling pathways in a concentration-dependent manner . Studies on steviol glycosides, including Reb I, have demonstrated enhanced glucose uptake in various cell types including HL-60 human leukemia cells, SH-SY5Y neuroblastoma cells, and rat fibroblasts, mimicking insulin response .
|
| Animal Protocol |
Toxicity studies have indicated that Reb I is generally safe in animal models, with dose-dependent effects observed. At lower dosages, Reb I stimulates GLP-1 release and improves glucose homeostasis . High doses should be approached with caution to avoid potential toxic effects . For formulation purposes, various injection and oral formulations are available, including DMSO/PEG300/Tween 80/saline combinations for parenteral administration and 0.5% CMC Na suspensions for oral administration .
|
| ADME/Pharmacokinetics |
The compound is metabolized through pathways involving glucosyltransferase enzymes . Its distribution within cells and tissues is facilitated by specific transporters and binding proteins .
|
| Toxicity/Toxicokinetics |
Rebaudioside I (Reb I) is classified as not a hazardous substance or mixture according to safety data sheets, with no GHS hazard labeling elements required . The compound is intended for research use only and not for human or veterinary use . The U.S. FDA issued a "no questions" letter for GRAS Notice No. 1178 regarding rebaudioside I obtained by enzymatic treatment of steviol glycosides, intended for use as a general-purpose sweetener in foods, excluding infant formula and meat and poultry products, at levels determined by good manufacturing practices . Toxicity studies indicate that Reb I is generally safe, though high doses should be approached with caution to avoid any potential toxic effects . Storage conditions recommend -20°C in dry, dark conditions for long-term stability, with stability of at least 12 months if stored properly .
|
| References | |
| Additional Infomation |
Rebaudioside I (Reb I) is a natural non-caloric sweetener isolated from *Stevia rebaudiana* Morita, belonging to the steviol glycoside family . It has the molecular formula C₅₀H₈₀O₂₈ and molecular weight of 1129.15 g/mol . Reb I is valued for its high sweetness intensity, approximately 250-450 times sweeter than sucrose . The compound is produced through enzymatic treatment of steviol glycosides purified from stevia leaves and has received FDA GRAS notification (GRN No. 1178) for use as a general-purpose sweetener in foods, excluding infant formula and meat and poultry products . Reb I exhibits anti-inflammatory properties by modulating inflammatory pathways and reducing markers of inflammation . It also demonstrates antioxidant effects that help mitigate oxidative stress in cells . Research has shown that Reb I can promote the growth of beneficial gut bacteria such as *Lactobacillus plantarum* while inhibiting pathogenic *Staphylococcus aureus* . The compound is typically stored as a white to off-white solid powder at -20°C, protected from light, and is soluble in DMSO and ethanol (with heating assistance) .
|
| Molecular Formula |
C50H80O28
|
|---|---|
| Molecular Weight |
1129.15341949463
|
| Exact Mass |
1128.483
|
| CAS # |
1220616-34-1
|
| PubChem CID |
92023627
|
| Appearance |
White to off-white solid powder
|
| LogP |
-4.4
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
28
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
78
|
| Complexity |
2080
|
| Defined Atom Stereocenter Count |
31
|
| SMILES |
O([C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)O)[C@@]12C(=C)C[C@]3(CC[C@@H]4[C@@](C(=O)O[C@H]5[C@@H]([C@H]([C@@H]([C@@H](CO)O5)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@@H](CO)O5)O)O)O)O)(C)CCC[C@@]4(C)[C@@H]3CC1)C2
|
| InChi Key |
BSVKOVOOJNJHBR-PBQKZBBNSA-N
|
| InChi Code |
InChI=1S/C50H80O28/c1-18-11-49-9-5-24-47(2,7-4-8-48(24,3)46(68)77-44-37(67)38(29(59)22(15-54)72-44)74-41-34(64)31(61)26(56)19(12-51)69-41)25(49)6-10-50(18,17-49)78-45-40(76-43-36(66)33(63)28(58)21(14-53)71-43)39(30(60)23(16-55)73-45)75-42-35(65)32(62)27(57)20(13-52)70-42/h19-45,51-67H,1,4-17H2,2-3H3/t19-,20-,21-,22-,23-,24+,25+,26-,27-,28-,29-,30-,31+,32+,33+,34-,35-,36-,37-,38+,39+,40-,41+,42+,43+,44+,45+,47-,48-,49-,50+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl] (1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate
|
| Synonyms |
REBAUDIOSIDE I; 1220616-34-1; Fema No. 4937; 1U83C5T5N8; UNII-1U83C5T5N8;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: 0.5 mg/mL (0.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8856 mL | 4.4281 mL | 8.8562 mL | |
| 5 mM | 0.1771 mL | 0.8856 mL | 1.7712 mL | |
| 10 mM | 0.0886 mL | 0.4428 mL | 0.8856 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
